retatrutide cas (LY3437943) | GCGR/GLP-1R/GIPR Agonist | 2381089-83-2 Triple G | C221H342N46O68 |

Overall the research confirmed an old observation that oral and intravenous glucose prompted different physiological responses (Marks, Samols)

A recent study in JAMA Ophthalmology suggests that patients using Ozempic and Wegovy may face a higher risk of developing non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition causing sudden vision loss

J Clin Med 2024;13:6

Estrogen receptor and Liver X receptor : biology and therapeutic potential in CNS diseases

These resolutions ended the legal basis for most 503B outsourcing facility compounding of these active ingredients

So, I think its going to be very enlightening over the next three to five years